Infinimmune has raised $75 million in Series A financing to advance its pipeline of human-derived antibody medicines, with the company preparing to move two lead programs for atopic dermatitis into first-in-human studies in 2027. The financing comes as the Alameda, California-based biotechnology company moves closer to clinical development with its antibody discovery approach.
The Series A round was co-led by Regeneron Ventures and Playground Global. The financing will support development of Infinimmune’s two lead atopic dermatitis programs, as well as the continued development of its broader antibody discovery platform and pipeline.
Regeneron Ventures and Playground Global Lead Funding
Several new and existing investors joined the financing. New investors include RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital and Wild Tree Ventures.
Existing investors that participated include Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures and Pear VC.
The new funding gives Infinimmune capital to advance its lead programs toward clinical testing while continuing work on additional antibody candidates. CEO and co-founder Wyatt McDonnell, Ph.D. said the financing will help the company bring its antibody programs into the clinic and reach important development milestones.
Two Antibody Programs Target Atopic Dermatitis
Infinimmune is developing two lead monoclonal antibodies for atopic dermatitis, a chronic inflammatory skin disease.
The first program, IFX-101, is a fully human monoclonal antibody that targets interleukin-22 (IL-22). The company is developing IFX-101 as a potential first- and best-in-class treatment for atopic dermatitis.
The second program, IFX-201, targets interleukin-13 (IL-13), a well-established pathway in atopic dermatitis. Infinimmune is positioning IFX-201 as a potential best-in-class treatment candidate. These descriptions are development goals from the company and have not yet been established through clinical trials.
Both programs are expected to enter first-in-human Phase 1 studies in 2027. The trials will provide the first clinical data on the safety and characteristics of these candidates in people.
Focus on Human-Derived Antibodies
Infinimmune’s approach centers on discovering antibodies directly from the human immune system. Its Anthrobody platform screens millions of individual memory B cells across hundreds of targets to identify fully human, naturally paired antibodies.
The company then applies its antibody engineering capabilities to select and optimize promising candidates. Infinimmune also uses its GLIMPSE antibody language models, which are designed around human antibody sequences, as part of its antibody engineering work.
The company says its approach is designed to find antibodies that have already demonstrated biological activity within human immune responses and then develop them as potential medicines. However, the effectiveness and safety of its lead candidates still need to be established through clinical development.
IL-22 Offers a Different Approach
IFX-101 gives Infinimmune an opportunity to explore IL-22 as a target in atopic dermatitis. According to CEO Wyatt McDonnell, there is currently no approved biologic targeting IL-22 for atopic dermatitis.
At the same time, IFX-201 is entering a competitive area because IL-13 is already an established target in atopic dermatitis treatments. Infinimmune is therefore seeking to differentiate its candidate through the properties of the antibody it has discovered and engineered.
The company has not yet generated clinical evidence showing that either candidate is safer or more effective than currently available treatments. Those questions will be addressed through future clinical trials.
Broader Antibody Pipeline
The company is also working on antibody programs beyond atopic dermatitis. Its pipeline includes IFX-301, which targets APRIL for IgA nephropathy, and IFX-401, which targets IL-17F for ulcerative colitis. Infinimmune continues to develop additional programs through its platform and partnerships.
The latest financing also builds on Infinimmune’s previous work with pharmaceutical companies. In March 2026, the company announced a multi-target antibody discovery collaboration with Merck. The agreement includes approximately $838 million in upfront and potential milestone payments, subject to the terms and achievement of applicable milestones. The figure represents potential deal value and is not funding already received by Infinimmune.
Funding Moves Infinimmune Toward the Clinic
The $75 million Series A marks an important financing milestone for Infinimmune as it transitions its human-derived antibody programs toward clinical testing.
With IFX-101 and IFX-201 expected to begin first-in-human studies in 2027, the company will soon have an opportunity to generate clinical data around its approach to antibody discovery and development.
For now, the financing provides Infinimmune with the resources to advance its lead atopic dermatitis programs, expand its broader pipeline, and continue developing its human-first antibody discovery platform. The next major milestone will be the start of clinical testing and the data that follows.
